GLP-1 agonists for metabolic disorders in schizophrenia

Patients with schizophrenia have a 2- to 3-fold higher mortality rate compared with the general population. A high prevalence of obesity, cardiometabolic disorders, and type 2 diabetes among these patients largely explains the increased cardiovascular risk (Correll et al., 2017).
Source: Schizophrenia Research - Category: Psychiatry Authors: Tags: Letter to the Editor Source Type: research